PharmAla Biotech and Awakn Life Sciences Partner to Make MDMA Accessible and Reliable

PharmAla Biotech Holdings Inc. (CSE: MDMA) is thrilled to announce that it has been named the exclusive supplier of MDMA to Awakn LS Europe Holdings Limited (CSE: AWKN). PharmAla is a leading biotechnology company that focuses on the research, development, and manufacturing of MDXX class molecules, such as MDMA. This new partnership will further strengthen PharmAla’s position in the market and help to bring safe and responsible MDMA use to Europe.

PharmAla and Awakn have a special relationship that dates back to the founding of Awakn. It was Prof. David Nutt, a founding board member of PharmAla, who left the board to become the Chief Research Officer of Awakn. To further strengthen this relationship, PharmAla is now supplying Awakn with engineering-grade and GMP LaNeo MDMA, to help advance their development program. Nick Kadysh, CEO of PharmAla, is excited to continue collaborating with Anthony and the Awakn team.

We are delighted to announce that PharmAla has been selected as the exclusive supplier of GLP and GMP MDMA for our research and development program. Our goal is to reduce the treatment time of MDMA-assisted therapy, and with the help of PharmAla, we are running a feasibility study to develop a proprietary formulation and optimized delivery route. We are confident that having a reliable partner like PharmAla as our API supplier will reduce risk and improve our chances of success.

On March 8th, PharmAla – the first publicly traded company to manufacture GMP MDMA and the first to make available two clinical-grade Psychedelic APIs – is hosting a webinar for researchers and clinicians to discuss the exciting changes announced by the Australian Therapeutic Goods Agency and the potential of their products to be used in upcoming clinical trials. Be sure to join the webinar and learn more about this innovative opportunity!

About PharmAla

PharmAla Biotech Holdings Inc. (CSE: MDMA) is a pioneering biotechnology company that is breaking the mold in the psychedelics industry. With a mission to alleviate the global backlog of generic, clinical-grade MDMA, PharmAla is the first publicly-traded company to manufacture clinical-grade MDMA. PharmAla is also committed to the development of novel drugs in the same class, with their lead drug candidate ALA-002 undergoing proof-of-concept research. By building excellent relationships with regulators, PharmAla is paving the way for a new era of success in the psychedelics industry.

About Awakn:

Awakn Life Sciences Corp. is a biotechnology pioneer, dedicated to developing groundbreaking therapeutics to treat addiction. We are particularly focused on Alcohol Use Disorder (AUD) – a condition impacting 285 million people worldwide – and striving to provide better treatment options than the current standard of care. Our mission is to bring meaningful hope to those in need, and our strategy involves commercializing our innovative R&D pipeline across multiple channels.

Leave a Comment